{
    "version": "v1.0",
    "description": "50 questions generated by Gemini 2.5 Pro (https://g.co/gemini/share/e9784eda9652) using 10 documents from our dataset with 5 questions generated per document.",
    "questions": [
        {
            "id": 1,
            "question": "What was the primary objective of the population-based study conducted in England between 1996 and 2013?",
            "answer": "The objective was to assess the effectiveness of the NHS Cancer Plan (2000) and subsequent national cancer policy initiatives in improving cancer survival and reducing socioeconomic inequalities in survival in England.",
            "reference": [
                "PMC5850596.plain.txt"
            ]
        },
        {
            "id": 2,
            "question": "How is 'net survival' defined in the English cancer policy study, and why is it a suitable measure for comparison between populations?",
            "answer": "Net survival is the probability of survival if cancer were the only possible cause of death. It is a suitable measure for comparisons because it is not dependent on differing mortality hazards from other causes between populations.",
            "reference": [
                "PMC5850596.plain.txt"
            ]
        },
        {
            "id": 3,
            "question": "For which specific cancers did the socioeconomic deprivation gap in survival widen between 1996 and 2013?",
            "answer": "The deprivation gap widened notably for brain tumours in men and for lung cancer in women. The gap for brain tumours in men widened by 5.1%, and for lung cancer in women, it widened by 1.1%.",
            "reference": [
                "PMC5850596.plain.txt"
            ]
        },
        {
            "id": 4,
            "question": "What overall conclusion did the English cancer policy study reach regarding the impact of national cancer strategies on one-year survival?",
            "answer": "The study found little evidence of a direct impact of national cancer strategies on one year survival and no evidence for a reduction in socioeconomic inequalities in cancer survival.",
            "reference": [
                "PMC5850596.plain.txt"
            ]
        },
        {
            "id": 5,
            "question": "What was the population size and age range for the cohort in the study on national cancer policies in England?",
            "answer": "The study included more than 3.5 million registered patients aged 15-99 with a diagnosis of one of the 24 most common primary, malignant, invasive neoplasms between 1996 and 2013.",
            "reference": [
                "PMC5850596.plain.txt"
            ]
        },
        {
            "id": 6,
            "question": "What is the name of the population-based cohort study focusing on adolescent and young adult cancer survivors, and what was the age range of patients at their initial diagnosis?",
            "answer": "The study is the Teenage and Young Adult Cancer Survivor Study (TYACSS). The cohort consists of survivors of cancer diagnosed when aged 15–39 years in England and Wales.",
            "reference": [
                "PMC6494975.plain.txt"
            ]
        },
        {
            "id": 7,
            "question": "According to the TYACSS study, what was the absolute excess risk (AER) of any subsequent primary neoplasm for female survivors of Hodgkin lymphoma?",
            "answer": "The absolute excess risk (AER) of any subsequent primary neoplasm was 55.7 per 10,000 person-years (95% CI 50.4–61.1) in female survivors of Hodgkin lymphoma.",
            "reference": [
                "PMC6494975.plain.txt"
            ]
        },
        {
            "id": 8,
            "question": "In the TYACSS study, for survivors of testicular cancer who had survived at least 30 years, which four subsequent primary neoplasms accounted for the largest percentages of the total excess number of neoplasms?",
            "answer": "For patients who had survived at least 30 years from testicular cancer diagnosis, the AERs for prostate cancer (20%), bladder cancer (18%), colorectal cancer (15%), and lung cancer (8%) accounted for a combined 61% of the total number of excess neoplasms.",
            "reference": [
                "PMC6494975.plain.txt"
            ]
        },
        {
            "id": 9,
            "question": "What key limitation did the TYACSS study have regarding its data source, and how did the researchers compensate for this?",
            "answer": "A limitation was the absence of detailed treatment information from the cancer registration data. In the absence of this data, the researchers chose to determine risks in relation to specific AYA cancer types.",
            "reference": [
                "PMC6494975.plain.txt"
            ]
        },
        {
            "id": 10,
            "question": "What was the 35-year cumulative incidence of all subsequent primary neoplasms for survivors of cervical cancer in the TYACSS study?",
            "answer": "The cumulative incidence of all subsequent primary neoplasms 35 years after diagnosis was 15.8% (95% CI 14.8–16.7) in survivors of cervical cancer.",
            "reference": [
                "PMC6494975.plain.txt"
            ]
        },
        {
            "id": 11,
            "question": "What was the purpose of the study involving the St Jude Lifetime Cohort and genetic risk?",
            "answer": "The purpose was to assess the contribution of pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes to the risk of subsequent neoplasms (SNs) among long-term survivors of childhood cancer.",
            "reference": [
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 12,
            "question": "In the St. Jude cohort study on genetic risk, what percentage of the childhood cancer survivors were found to have pathogenic/likely pathogenic (P/LP) mutations?",
            "answer": "Pathogenic/likely pathogenic mutations were identified in 5.8% (95% CI, 5.0% to 6.7%) of the 3,006 survivors.",
            "reference": [
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 13,
            "question": "Among nonirradiated childhood cancer survivors, pathogenic mutations were associated with an increased risk of which three outcomes?",
            "answer": "Among nonirradiated survivors, mutations were associated with increased rates of developing any subsequent neoplasm (RR, 4.7), breast cancer (RR, 7.7), nonmelanoma skin cancer (RR, 11.0), and two or more histologically distinct SNs (RR, 18.6).",
            "reference": [
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 14,
            "question": "What was the study's primary recommendation regarding genetic counseling for childhood cancer survivors?",
            "answer": "The findings support the referral of all survivors for genetic counseling for potential clinical genetic testing. This should be prioritized for nonirradiated survivors with any subsequent neoplasm and for survivors with breast cancer or sarcoma in the field of prior irradiation.",
            "reference": [
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 15,
            "question": "For irradiated survivors in the St. Jude genetic risk study, mutations were linked to a significantly increased rate of which two subsequent cancers?",
            "answer": "Among irradiated survivors, mutations were associated with significantly increased rates of breast cancer (Relative Rate, 13.9) and sarcoma (Relative Rate, 10.6).",
            "reference": [
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 16,
            "question": "What three malignancies comprise myeloproliferative neoplasms (MPN)?",
            "answer": "Myeloproliferative neoplasms (MPN) comprise polycythemia vera, essential thrombocythemia and myelofibrosis.",
            "reference": [
                "PMC7030948.plain.txt"
            ]
        },
        {
            "id": 17,
            "question": "In the study of 2035 MPN patients, what percentage had mutations in JAK2, CALR, or MPL as their only identified abnormality?",
            "answer": "In the study cohort, JAK2, CALR or MPL mutations were the sole abnormality in 45% of patients.",
            "reference": [
                "PMC7030948.plain.txt"
            ]
        },
        {
            "id": 18,
            "question": "How many distinct genomic subgroups of MPNs were defined by the study, and what did these subgroups help predict?",
            "answer": "The study defined 8 genomic subgroups which exhibited distinct clinical phenotypes, including diagnostic blood counts, risk of leukemic transformation, and event-free survival.",
            "reference": [
                "PMC7030948.plain.txt"
            ]
        },
        {
            "id": 19,
            "question": "According to the MPN heterogeneity study, what is the benefit of integrating genomic data with clinical parameters?",
            "answer": "The integration of genomic data with clinical parameters enables personalised predictions of patient outcome and will support the management of MPN patients.",
            "reference": [
                "PMC7030948.plain.txt"
            ]
        },
        {
            "id": 20,
            "question": "The study on MPN heterogeneity found that the number of driver mutations increased with what two factors?",
            "answer": "The number of driver mutations was found to increase with age and with advanced disease.",
            "reference": [
                "PMC7030948.plain.txt"
            ]
        },
        {
            "id": 21,
            "question": "What is the Genotyping of Transcriptomes (GoT) method, and what two processes does it combine?",
            "answer": "Genotyping of Transcriptomes (GoT) is a method that was developed to link somatic mutations to cell identity. It integrates genotyping with high-throughput droplet-based single-cell RNA-seq.",
            "reference": [
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 22,
            "question": "In the GoT study of CALR-mutated myeloproliferative neoplasms (MPN), where was the fitness advantage of the mutation most pronounced?",
            "answer": "The fitness impact of CALR mutations was found to increase with myeloid differentiation, with the CALR mutated cell frequency being higher in committed myeloid progenitors, especially megakaryocytic progenitors (MkPs).",
            "reference": [
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 23,
            "question": "What technical limitation of the standard GoT method is 'Circularization GoT' designed to overcome?",
            "answer": "Standard GoT is limited by the distance of the mutation from the transcript ends. 'Circularization GoT' was developed to enable genotyping of mutations that are distant from transcript ends, such as the JAK2V617F mutation which is approximately 3 kb from the end.",
            "reference": [
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 24,
            "question": "The GoT study identified the unfolded protein response (UPR) as a predominant outcome of CALR mutations. What specific branch of the UPR was activated?",
            "answer": "The study repurposed GoT to probe for the spliced region of XBP1, demonstrating that CALR mutations induce activation of the IRE1-branch of the UPR in both hematopoietic stem progenitor cells (HSPCs) and megakaryocytic progenitors (MkPs).",
            "reference": [
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 25,
            "question": "Besides the unfolded protein response, what other pathway was found to be upregulated by CALR mutations specifically in uncommitted stem cells?",
            "answer": "Differential gene expression analysis in hematopoietic stem progenitor cells (HSPCs) revealed an upregulation of the NF-κB pathway in mutant cells compared to wildtype cells.",
            "reference": [
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 26,
            "question": "What is the definition of Glycemic Index (GI) and Glycemic Load (GL)?",
            "answer": "The Glycemic Index (GI) is an index of carbohydrate foods indicating how quickly they cause an increase in blood glucose levels. The Glycemic Load (GL) is the product of the GI and the total available carbohydrate content in a given amount of food.",
            "reference": [
                "PMC6835610.plain.txt"
            ]
        },
        {
            "id": 27,
            "question": "According to the updated meta-analysis, a high Glycemic Index (GI) was associated with an increased risk for which three types of cancer?",
            "answer": "A high Glycemic Index was associated with small increased risks of colorectal cancer (summary RR: 1.20), bladder cancer (summary RR: 1.25), and kidney cancer (summary RR: 1.16).",
            "reference": [
                "PMC6835610.plain.txt"
            ]
        },
        {
            "id": 28,
            "question": "In the meta-analysis, what was the summary relative risk of breast cancer for high versus low Glycemic Load (GL) intake specifically among premenopausal women?",
            "answer": "The summary relative risk of breast cancer for the highest versus the lowest category of GL intake was 1.16 (95% CI, 1.00–1.34) for premenopausal breast cancer.",
            "reference": [
                "PMC6835610.plain.txt"
            ]
        },
        {
            "id": 29,
            "question": "Did the meta-analysis find a significant association between GI or GL and the risk of developing stomach, prostate, or lung cancer?",
            "answer": "No, the analysis found that stomach, prostate, and lung cancers were not associated with either Glycemic Index (GI) or Glycemic Load (GL).",
            "reference": [
                "PMC6835610.plain.txt"
            ]
        },
        {
            "id": 30,
            "question": "What biological mechanism is suggested to explain the modest association between high GI/GL diets and cancer risk?",
            "answer": "Long-term consumption of high GI/GL diets can lead to chronically high blood glucose and insulin concentrations. Insulin can increase bioactive IGF-1, which promotes cancer development by inhibiting apoptosis and stimulating cell proliferation.",
            "reference": [
                "PMC6835610.plain.txt"
            ]
        },
        {
            "id": 31,
            "question": "What are the three main clinical tasks in cancer imaging where Artificial Intelligence (AI) finds significant utility?",
            "answer": "AI finds great utility in performing three main clinical tasks within cancer imaging: the detection, characterization, and monitoring of tumors.",
            "reference": [
                "PMC6403009.plain.txt"
            ]
        },
        {
            "id": 32,
            "question": "What is 'imaging genomics'?",
            "answer": "Imaging genomics is an emerging field that correlates radiographic imaging features with biological data, such as somatic mutations, gene expression, chromosome copy number, or other molecular signatures.",
            "reference": [
                "PMC6403009.plain.txt"
            ]
        },
        {
            "id": 33,
            "question": "What is 'pseudoprogression' in patients with glioblastoma, and what percentage of patients experience it?",
            "answer": "Pseudoprogression is the enlargement of a contrast-enhancing lesion that later stabilizes or resolves without changes in treatment. It is observed in 20% to 30% of glioblastoma patients who receive standard radiation with adjuvant temozolomide.",
            "reference": [
                "PMC6403009.plain.txt"
            ]
        },
        {
            "id": 34,
            "question": "According to the article, what is a major obstacle to developing automated clinical AI solutions?",
            "answer": "A major obstacle is the curation of medical data. Data is rarely curated in terms of labeling, annotations, segmentations, or quality assurance, and this process requires trained professionals, making it expensive in both time and cost.",
            "reference": [
                "PMC6403009.plain.txt"
            ]
        },
        {
            "id": 35,
            "question": "What was the key finding of the National Lung Screening Trial (NLST) regarding low-dose CT screening?",
            "answer": "The National Lung Screening Trial (NLST) demonstrated that screening with low-dose CT (LDCT) was associated with a significant 20% reduction in overall mortality among high-risk current and former smokers.",
            "reference": [
                "PMC6403009.plain.txt"
            ]
        },
        {
            "id": 36,
            "question": "What was the purpose of the study that used the COVID and Cancer Research Network (CCRN)?",
            "answer": "The purpose was to provide quantitative reports on the impact that efforts to control the COVID-19 pandemic have had on the normal course of cancer diagnosis and treatment encounters.",
            "reference": [
                "PMC7444638.plain.txt"
            ]
        },
        {
            "id": 37,
            "question": "During the COVID-19 pandemic, by what percentage did screenings for breast and colorectal cancer decline in April 2020 compared to April 2019?",
            "answer": "Cancer screenings declined drastically, with breast cancer screenings dropping by -89.2% and colorectal cancer screenings by -84.5%.",
            "reference": [
                "PMC7444638.plain.txt"
            ]
        },
        {
            "id": 38,
            "question": "Which three cancer types saw the largest decreases in patient encounters in April 2020 versus April 2019?",
            "answer": "The largest decreases in cohort size for patient encounters were for breast cancer (-47.7%), prostate cancer (-49.1%), and melanoma (-51.8%).",
            "reference": [
                "PMC7444638.plain.txt"
            ]
        },
        {
            "id": 39,
            "question": "What future consequence is suggested by the steep decreases in cancer screening and new cancer diagnoses during the pandemic?",
            "answer": "The decreases suggest the possibility of a future increase in patients being initially seen with later-stage cancer, as well as an increased demand for cancer screening procedures as delayed tests are rescheduled.",
            "reference": [
                "PMC7444638.plain.txt"
            ]
        },
        {
            "id": 40,
            "question": "How did the study compare patient encounter data from the pre-COVID and pandemic periods?",
            "answer": "The study compared cancer cohorts identified by querying encounter data from a pre-COVID period (January 2019-April 2019) with data from the pandemic period (January 2020-April 2020).",
            "reference": [
                "PMC7444638.plain.txt"
            ]
        },
        {
            "id": 41,
            "question": "What was the main goal of the St Jude Lifetime Cohort study on DNA repair genes?",
            "answer": "The main purpose was to investigate the combined effect of cancer treatment and pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) to identify childhood cancer survivors at an increased risk of subsequent neoplasms (SNs).",
            "reference": [
                "PMC7430217.plain.txt"
            ]
        },
        {
            "id": 42,
            "question": "In the study of 4,402 childhood cancer survivors, what percentage had pathogenic germline mutations (PGMs) in DNA repair genes?",
            "answer": "Of the 4,402 survivors, 508 (11.5%) were identified as having pathogenic germline mutations in 98 DNA repair genes.",
            "reference": [
                "PMC7430217.plain.txt"
            ]
        },
        {
            "id": 43,
            "question": "Mutations in homologous recombination (HR) genes were significantly associated with an increased rate of subsequent sarcoma under what specific treatment condition?",
            "answer": "Mutations in homologous recombination (HR) genes were associated with an increased rate of subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9).",
            "reference": [
                "PMC7430217.plain.txt"
            ]
        },
        {
            "id": 44,
            "question": "In the DNA repair gene study, how many genes and DNA repair pathways were evaluated for mutations?",
            "answer": "Pathogenic germline mutations were evaluated in 127 genes from 6 major DNA repair pathways.",
            "reference": [
                "PMC7430217.plain.txt"
            ]
        },
        {
            "id": 45,
            "question": "What is the potential benefit of the findings from the DNA repair gene study for high-risk survivors?",
            "answer": "The findings can help identify high-risk survivors who may benefit from genetic counseling or testing of DNA repair genes, which could inform personalized cancer surveillance and prevention strategies.",
            "reference": [
                "PMC7430217.plain.txt"
            ]
        },
        {
            "id": 46,
            "question": "In the KPSC cohort study, how much greater was the risk for adolescent and young adult (AYA) cancer survivors to develop a second malignant neoplasm (SMN) compared to a matched cohort?",
            "answer": "AYA cancer survivors had a 2.6-fold greater risk of developing a second malignant neoplasm compared with the matched comparison cohort, with an incidence rate ratio (IRR) of 2.6 (95% CI, 2.4-2.9).",
            "reference": [
                "PMC6563559.plain.txt"
            ]
        },
        {
            "id": 47,
            "question": "According to the KPSC study, which five factors were associated with an increased risk of developing an SMN among AYA cancer survivors?",
            "answer": "Among survivors of AYA cancer, older age at diagnosis, female sex, white race/ethnicity, advanced stage at first cancer diagnosis, and use of radiotherapy were associated with an increased risk of SMN.",
            "reference": [
                "PMC6563559.plain.txt"
            ]
        },
        {
            "id": 48,
            "question": "For survivors of breast cancer in the KPSC cohort, what was the incidence rate ratio (IRR) for developing another breast cancer?",
            "answer": "Survivors of breast cancer had an elevated risk for an SMN of the same organ, with an IRR of 5.6 (95% CI, 4.6-6.8).",
            "reference": [
                "PMC6563559.plain.txt"
            ]
        },
        {
            "id": 49,
            "question": "How did the all-cause mortality rate for AYA survivors who developed an SMN compare to those who did not?",
            "answer": "AYA cancer survivors who developed an SMN had an all-cause mortality rate 7.2 times greater than survivors who did not develop an SMN.",
            "reference": [
                "PMC6563559.plain.txt"
            ]
        },
        {
            "id": 50,
            "question": "What was the 20-year cumulative incidence of a second malignant neoplasm (SMN) in the KPSC cohort of AYA cancer survivors?",
            "answer": "The 20-year cumulative incidence of SMN was 12.5% in survivors of AYA cancer.",
            "reference": [
                "PMC6563559.plain.txt"
            ]
        }
    ]
}